Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of TAK-279 in Hepatic Impairment
NCT05976321Phase 1Completed
- Sponsor
- Takeda
- Start
- Sep 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zasocitinib in psoriasis and psoriatic arthritis (PsA) (3 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration at Day 10, Area Under the Plasma Concentration-Time Curve to Last Quantifiable Concentration at Day 10 and 1 more. Started Sep 2023; status: completed.
02
Drugs
zasocitinib
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05976321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05976321.